First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial. (linkinghub.elsevier.com)

Authors: Slomovitz BM … Pignata S Journal: The Lancet Published: 2026-10-26 DOI: https://doi.org/10.1016/S0140-6736(26)02095-7